Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307149 · ClinicalTrials.gov registry record · Phase 1
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
A Phase 1 study, sponsored by Viralytics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02307149 is a Phase 1 study that has completed, run by Viralytics. The registered enrollment target is 50 participants.
The verdict
NCT02307149, a Phase 1 study, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.
Interventions
- DRUG Ipilimumab
- BIOLOGICAL CAVATAK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02307149
The ClinicalTrials.gov registry entry for NCT02307149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viralytics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT02307149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02307149 about?
NCT02307149 is a clinical study titled "Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)". Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.
What is the current status of trial NCT02307149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-05-05. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT02307149?
The interventions under investigation include: Ipilimumab (DRUG), CAVATAK (BIOLOGICAL).
Who is sponsoring clinical trial NCT02307149?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.